VYTRUS BIOTECH EO -01 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

VYTRUS BIOTECH EO -01 (V5P) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read V5P total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€600.00
≈ $701.46 USD Cash + Short-term Investments

Total Assets

€14.66 Million
≈ $17.14 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how VYTRUS BIOTECH EO -01's Asset Resilience Ratio has changed over time. See V5P total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down VYTRUS BIOTECH EO -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VYTRUS BIOTECH EO -01 stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €600.00 0.0%
Total Liquid Assets €600.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: VYTRUS BIOTECH EO -01 maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

VYTRUS BIOTECH EO -01 Industry Peers by Asset Resilience Ratio

Compare VYTRUS BIOTECH EO -01's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
Biotechnology 23.64%
Enveric Biosciences Inc
NASDAQ:ENVB
Biotechnology 0.75%
ABEONA THERAPEUT. DL-01
F:PCJ
Biotechnology 51.45%
SynCore Biotechnology Co Ltd
TWO:4192
Biotechnology 2.58%
Uniqure NV
NASDAQ:QURE
Biotechnology 10.94%
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Biotechnology 0.00%
Altimmune Inc
NASDAQ:ALT
Biotechnology 82.06%
Kura Oncology Inc
NASDAQ:KURA
Biotechnology 70.17%

Annual Asset Resilience Ratio for VYTRUS BIOTECH EO -01 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for VYTRUS BIOTECH EO -01.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% €600.00
≈ $701.46
€14.66 Million
≈ $17.14 Million
0.00pp
2024-12-31 0.01% €600.00
≈ $701.46
€11.13 Million
≈ $13.01 Million
0.00pp
2023-12-31 0.01% €600.00
≈ $701.46
€9.31 Million
≈ $10.89 Million
0.00pp
2021-12-31 0.01% €522.14
≈ $610.44
€7.18 Million
≈ $8.40 Million
--
pp = percentage points

About VYTRUS BIOTECH EO -01

F:V5P Germany Biotechnology
Market Cap
$138.40 Million
€118.38 Million EUR
Market Cap Rank
#18237 Global
#1705 in Germany
Share Price
€15.75
Change (1 day)
-4.55%
52-Week Range
€3.02 - €21.60
All Time High
€21.60
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more